Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 7Recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 3Neoplasms 3Leukemia, Myeloid, Acute 3Breast Neoplasms 3Pancreatic Neoplasms 2Neoplastic Cells, Circulating 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Myeloid 1Rectal Neoplasms 1Pruritus 1Polycystic Ovary Syndrome 1Papillomavirus Infections 1Pancreatic Adenocarcinoma 1Overweight 1Oropharyngeal Neoplasms 1Opioid-Related Disorders 1Obesity 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Liver Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2Specimen Handling 1Restraint, Physical 1Probiotics 1Independent Medical Evaluation 1Hepatitis A Vaccines 1Data Collection 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Papillomavirus Infections × Blood Specimen Collection × Clear all
NCT02100618 2015-07-20

Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study

GlaxoSmithKline

Phase 3 Withdrawn

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡